IRONWOOD PHARMACEUTICALS, INC. Amortization of Debt Discount (Premium)
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Amortization of Debt Discount (Premium) of $22.26 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-02-16.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2023-02-16
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt discount (premium) for the quarter ending 2021-12-31 was $5.71M, a 7.01% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt discount (premium) for the quarter ending 2021-09-30 was $5.61M, a 7.00% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt discount (premium) for the quarter ending 2021-06-30 was $5.52M, a 6.98% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt discount (premium) for the quarter ending 2021-03-31 was $5.42M, a 7.00% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt discount (premium) for fiscal 2021 was $22.26M, a 7.00% increase from fiscal 2020.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt discount (premium) for fiscal 2020 was $20.80M, a 17.63% increase from fiscal 2019.
- IRONWOOD PHARMACEUTICALS, INC. amortization of debt discount (premium) for fiscal 2019 was $17.68M.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2021-12-31 | $5.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $11.32M derived: sum of 2 quarters · filed 2023-02-16 | $16.83M derived: sum of 3 quarters · filed 2023-02-16 | $22.26M 10-K · filed 2023-02-16 |
| 2021-09-30 | $5.61M 10-Q · filed 2022-11-03 | $11.13M derived: sum of 2 quarters · filed 2022-11-03 | $16.55M 10-Q · filed 2022-11-03 | $21.88M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-06-30 | $5.52M 10-Q · filed 2022-08-04 | $10.94M 10-Q · filed 2022-08-04 | $16.27M derived: sum of 3 quarters · filed 2023-02-16 | $21.52M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-03-31 | $5.42M 10-Q · filed 2022-05-05 | $10.76M derived: sum of 2 quarters · filed 2023-02-16 | $16.00M derived: sum of 3 quarters · filed 2023-02-16 | $21.16M derived: sum of 4 quarters · filed 2023-02-16 |
| 2020-12-31 | $5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $10.58M derived: sum of 2 quarters · filed 2023-02-16 | $15.73M derived: sum of 3 quarters · filed 2023-02-16 | $20.80M 10-K · filed 2023-02-16 |
| 2020-09-30 | $5.24M 10-Q · filed 2021-11-04 | $10.40M derived: sum of 2 quarters · filed 2021-11-04 | $15.47M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $5.16M 10-Q · filed 2021-08-05 | $10.22M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $5.07M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $17.68M 10-K · filed 2022-02-18 | |||
| 2015-09-30 | $3.00M 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |